This page shows the latest Poseida Therapeutics news and features for those working in and with pharma, biotech and healthcare.
San Diego firm joins crowded field. Gene-engineering specialist Poseida Therapeutics is launching its own challenger into the crowded CAR-T pipeline for multiple myeloma, and has just gained backing from ... Poseida’s suite of proprietary gene editing
Another anti-BCMA player – Poseida Therapeutics – presented preliminary data on 19 myeloma patients who had a median of six prior lines of therapy.
Biotech, Poseida Therapeutics, CARsgen Therapeutics and Memorial Sloan Kettering Cancer Centre showing impressive efficacy results in multiple myeloma.
Earlier this week, J&J licensed rights to a technology used in the development of another hot area in immuno-oncology - chimeric antigen receptor therapies (CAR-T) to Poseida Therapeutics. ... Poseida wants to screen the molecules for activity against
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...